Journal
CANCERS
Volume 11, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/cancers11050674
Keywords
CAR-T; immunotherapy; alpha v beta 6; integrin; homing; chemokine receptor; solid tumor; cancer; chimeric antigen receptor; T-cell
Categories
Funding
- Pancreatic Cancer UK
- Kings Health Partners MRC Confidence in Concepts
- Cancer Research UK (CRUK) [A21623]
- MRC [MC_PC_14105] Funding Source: UKRI
Ask authors/readers for more resources
Despite the unprecedented clinical success of chimeric antigen receptors (CAR) T-cells against haematological malignancy, solid tumors impose a far greater challenge to success. Largely, this stems from an inadequate capacity of CAR T-cells that can traffic and maintain function within a hostile microenvironment. To enhance tumor-directed T-cell trafficking, we have engineered CAR T-cells to acquire heightened responsiveness to interleukin (IL)-8. Circulating IL-8 levels correlate with disease burden and prognosis in multiple solid tumors in which it exerts diverse pathological functions including angiogenesis, support of cancer stem cell survival, and recruitment of immunosuppressive myeloid cells. To harness tumor-derived IL-8 for therapeutic benefit, we have co-expressed either of its cognate receptors (CXCR1 or CXCR2) in CAR T-cells that target the tumor-associated alpha v beta 6 integrin. We demonstrate here that CXCR2-expressing CAR T-cells migrate more efficiently towards IL-8 and towards tumor conditioned media that contains this cytokine. As a result, these CAR T-cells elicit superior anti-tumor activity against established alpha v beta 6-expressing ovarian or pancreatic tumor xenografts, with a more favorable toxicity profile. These data support the further engineering of CAR T-cells to acquire responsiveness to cancer-derived chemokines in order to improve their therapeutic activity against solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available